RxDoctor Payments Data

Anil Patel, MD

Psychiatry · San Marcos, CANPI 1164462164

Payments from drug & device makers

$798in general payments, 2019–2025

Across 43 payments — averaging $18.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$204
  • Sunovion Pharmaceuticals Inc.$111
  • Teva Pharmaceuticals USA, Inc.$86
  • Otsuka America Pharmaceutical, Inc.$65
  • Alkermes, Inc.$57
  • Supernus Pharmaceuticals, Inc.$53
  • plus $221 from 7 others

What the payments were for

  • Food & beverage$76696%
  • Education$324%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$798 in reported general payments places this provider in the 70th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$23,105
Medicare patients
34
Services billed
171

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole24$42,557
VraylarCariprazine Hcl15$20,476
CaplytaLumateperone Tosylate12$18,063
TrintellixVortioxetine Hydrobromide17$14,437
Asenapine Maleate15$4,558
VyvanseLisdexamfetamine Dimesylate11$3,992
Clozapine41$3,285
Bupropion XlBupropion Hcl116$2,795
Aripiprazole19$2,632
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine24$2,421
Venlafaxine Hcl ErVenlafaxine Hcl19$1,818
Quetiapine Fumarate99$1,429
Duloxetine Hcl79$1,364
Trazodone Hcl78$1,295
Lamotrigine143$1,128

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$65$42,55724 claims
AbbVieVraylar$32$20,47615 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$24$18,42828 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$19$18,06312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,954 psychiatry providers in California.

Other psychiatry in San Marcos

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →